Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.
It is very uncertain whether celecoxib changes number experiencing any serious adverse events compared with tNSAIDs (very low certainty).
It is very uncertain whether celecoxib changes number experiencing any serious adverse events compared with placebo (very low certainty).
It is very uncertain whether lactulose changes non‐serious adverse events (secondary outcome) compared with lactitol (very low certainty).
It is very uncertain whether non‐absorbable disaccharides changes non‐serious adverse events (secondary outcome) compared with placebo/no intervention (very low certainty).
It is very uncertain whether botulinum neurotoxin B changes proportion of participants with adverse events compared with placebo (very low certainty).
It is very uncertain whether pre‐hospital cooling changes adverse events ‐ re‐arrest after randomization compared with in‐hospital cooling (very low certainty).
Topical acyclovir showed no clear difference in adverse events ‐ pain with topical application compared with placebo (low certainty).
The review found no eligible studies for this question.
The review found no eligible studies for this question.
Uterine artery embolization (UAE) showed no clear difference in adverse events: intra‐procedural complications compared with surgery (low certainty).
It is very uncertain whether infliximab combined with purine analogues changes serious adverse events (at 48 weeks to 2 years) compared with purine analogues (very low certainty).
Favipiravir showed no clear difference in serious adverse events attributable to the drug compared with no treatment, supportive treatment, or other antiviral treatment (low certainty).
Anticoagulant agent may leads to lower adverse events (hospital records/every 6 weeks) compared with placebo (low certainty).
It is very uncertain whether helium changes pneumoperitoneum‐related serious adverse events compared with carbon dioxide (very low certainty).
It is very uncertain whether clonidine and opioid changes adverse events (treatment related) To discharge compared with opioid alone (very low certainty).
It is very uncertain whether clonidine and opioid changes adverse events (treatment related) To discharge compared with phenobarbital and opioid (very low certainty).
Morphine showed no clear difference in adverse events (treatment related) To discharge compared with methadone (low certainty).
It is very uncertain whether morphine changes adverse events (treatment‐related) To discharge compared with buprenorphine (very low certainty).